Tykerb works inside of cancer cells. It binds to the inside of two types of receptors: epidermal growth factor receptor (EGFR) and human epidermal receptor type 2 (HER2). These two receptors are important for the growth of breast cancer and cells, and Tykerb (when used in combination with Xeloda) helps to slow down this growth.
Tykerb is not approved to treat cancer in children or adolescents. Talk to your healthcare provider about the benefits and risks of using the drug in children or adolescents.
On occasion, your healthcare provider may recommend Tykerb for something other than breast cancer. At this time, there are no universally accepted off-label Tykerb uses.